lyvispah Drug Patent Profile
✉ Email this page to a colleague
When do Lyvispah patents expire, and what generic alternatives are available?
Lyvispah is a drug marketed by Amneal and is included in one NDA. There are five patents protecting this drug.
This drug has ten patent family members in eight countries.
The generic ingredient in LYVISPAH is baclofen. There are twenty-one drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lyvispah
A generic version of lyvispah was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
Summary for lyvispah
International Patents: | 10 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 150 |
Patent Applications: | 5,044 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for lyvispah |
What excipients (inactive ingredients) are in lyvispah? | lyvispah excipients list |
DailyMed Link: | lyvispah at DailyMed |
Pharmacology for lyvispah
Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
Mechanism of Action | GABA A Agonists GABA B Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for lyvispah
US Patents and Regulatory Information for lyvispah
lyvispah is protected by seven US patents.
Patents protecting lyvispah
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD FOR TREATING SPASTICITY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-001 | Nov 22, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-003 | Nov 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-001 | Nov 22, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-001 | Nov 22, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-003 | Nov 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-002 | Nov 22, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-002 | Nov 22, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lyvispah
See the table below for patents covering lyvispah around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 7444967 | ⤷ Try a Trial | |
Canada | 3148812 | FORMULATIONS STABILISEES DE DERIVES DE L'ACIDE BUTANOIQUE DU TYPE 4-AMINO-3-SUBSTITUES (STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES) | ⤷ Try a Trial |
Australia | 2020323846 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ⤷ Try a Trial |
Japan | 2022544901 | 4-アミノ-3-置換ブタン酸誘導体の安定化製剤 | ⤷ Try a Trial |
European Patent Office | 4003323 | FORMULATIONS STABILISÉES DE DÉRIVÉS DE L'ACIDE BUTANOÏQUE DU TYPE 4-AMINO-3-SUBSTITUÉS (STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2021021277 | ⤷ Try a Trial | |
Mexico | 2022001139 | FORMULACIONES ESTABILIZADAS DE DERIVADOS DE ACIDO 4-AMINO-3-SUSTITUIDO BUTANOICO. (STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES.) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |